Board summary
Key figures
95,758
Registered population
66.0% aged 18–64
14.2%
Aged 65+
ICB 20.0% · England 17.9%
13.5%
Ethnic minority (non-White)
9.9% Asian · England 9.6%
47.2%
In IMD quintile 1
ICB 30.6% · England 21.0%
~37,813
Core20 residents (est.)
Resident basis; registered basis ~51,845 · see page 3
12,257
Hypertension register
+6.88% in 3 yrs · England +5.60%
1,211
SMI register
54% of Preston's
1,719
COPD register
Reviews -0.97% in 3 yrs
Forecast to 2030
14,587
Hypertension patients, 2030
+2,330 on today
71.4%
QRISK ≥20% on statins, 2030
+2.13pp over 3 yrs
3.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
MMR dose gap at age five.
Age-five coverage drops from 95.5% for dose 1 to 86.2% for dose 2 (below the 95.0% target), which may reflect recall gaps, unverified locally.
Asthma reviews fell against England growth.
Annual asthma reviews fell 6.1% over 2023 to 2025 to 63.1% (England +4.4%), leaving a scale gap of 2,052 patients that may reflect recall.
Heart failure and BP delivery outpaces England.
Heart failure reviews rose +15.3% over 2023 to 2025 to 81.0% (England +8.7%), alongside under-80 blood pressure control rising +8.6% (England +3.2%).
Population, age and ethnicity
Working-age adults form 66.0% of patients while older people trail England at 14.2%
The PCN registers 95,758 patients (summing practice lists yields 102,231, requiring period reconciliation). Working-age adults aged 18-64 comprise 66.0% of patients, above Preston (64.9%), the ICB (60.4%) and England (62.7%). Those aged 65+ account for 14.2% (Preston 12.7%, ICB 20.0%, England 17.9%), while aged 0-17 represent 19.8% (Preston 22.4%, ICB 19.6%, England 19.6%). Census resident data indicates an 86.5% White and 9.9% Asian population (Preston 20.2%, ICB 9.4%, England 9.6%), alongside a 13.5% non-White share. Projected list growth to 2030 is 3.0% (Preston 4.3%, ICB 1.7%, England 2.3%) under an unverified projection method.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Preston local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Preston LA) | 1,847 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Preston LA) | 950 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Preston LA) | 13.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation and Core20
Core20 cohort (IMD quintile 1) is 47.2% at PCN level, above Preston (46.4%), NHS Lancashire and South Cumbria Integrated Care Board (30.6%), and England (21.0%), sitting 26.1 percentage points above England. Core20 reflects the most deprived 20% of national areas rather than a local performance target.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,211
SMI register
1.30% recorded prevalence
565
Learning disability register
0.60% recorded prevalence
44
Care homes, 1,427 beds
In the PCN catchment
9.3%
Provide unpaid care
Preston, Census 2021
The PCN records 1,211 severe mental illness patients (1.3% prevalence; Preston 1.4%, ICB 1.2%, England 1.0%) and 565 learning disability patients (0.6% prevalence; Preston 0.7%, ICB 0.6%, England 0.6%). The catchment includes 44 care homes with 1,427 beds, though site capacity does not confirm patient registrations.
Severe mental illness: physical health checks
Severe mental illness recorded prevalence is 1.3% (1,211 patients). Although 3-year BMI recording rose +10.2 pp (England +5.1 pp), 12-month blood pressure checks at 82.1% and BMI checks at 80.0% trail England (83.4% and 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,257
Hypertension register
+6.88%
Register growth, 3 yrs
Preston +5.93% · England +5.60%
+5.32pp
BP control, under 80
≤140/90 · +0.75pp aged 80+
+2,330
More patients by 2030
Forecast 14,587 (14.98%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.1% (12,257 patients), below Preston (13.8%), England (15.2%), and NHS Lancashire and South Cumbria Integrated Care Board (17.2%). Three-year register change reached +6.9% over 2023 to 2025 (England +5.6%). For patients under 80 with hypertension, blood pressure control to <= 140/90 mmHg improved +8.6% over 2023 to 2025 (England +3.2%) to 66.9% (England 67.8%). For patients aged 80 and over, blood pressure control to <= 150/90 mmHg reached 79.7% (England 81.2%, ICB 81.8%). Lower recorded control among patients aged 80 and over compared with national benchmarks could reflect medication adherence or clinical thresholds, unverified locally; an audit would test this.
Lipids and statins
Patients with QRISK >= 20% treated with lipid-lowering therapy reached 66.9% (England 63.6%), and CKD treatment reached 75.9% (England 70.3%). However, statin therapy in diabetic patients aged 40 and over without CVD fell 1.3% over 2023 to 2025 (England +2.1%) to 74.6% (England 73.2%). Falling diabetic statin therapy over three years may indicate uneven annual.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 158,012 | £1.50 | £1.64 | £1.86 | £237,018 |
| Cardiovascular (all), 2025 | 224,418 | £3.13 | £3.38 | £3.33 | £702,428 |
In 2026, the PCN prescribed 158,012 lipid-regulating items at £1.50 per item (England £1.86, ICB £1.64), spending £56,884 less than at England's unit cost across 158,012 items. Prescribing per 1,000 adults aged 18 and over was 2,056 items (England 4,100, ICB 2,615). Unit cost does not measure prescribing efficiency or appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−6.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.02%
Asthma prevalence, PCN 3-yr % change
Annual asthma reviews fell 6.1% over 2023 to 2025 (England +4.4%) to 63.1% (Preston 66.8%, ICB 65.0%, England 65.7%), indicating an unadjusted scale gap of 2,052 patients without a recorded review across the 5,566-patient register. Youth asthma prescribing reached 1,653 items per 1,000 aged 5-19 (England 1,488). COPD recorded prevalence is 1.8% (1,719 patients), where 12-month reviews reached 78.2% (England 76.4%) despite falling 1.0% over three years (England +2.8%). Falling asthma review completion alongside elevated youth prescribing could reflect unmonitored exacerbation risk.
Cancer register and children's immunisation
Cancer recorded prevalence is 3.2% (2,981 patients; England 3.8%). In Q1 2025/26 immunisations, 6-in-1 coverage at 12 months was 84.5% (below the 95.0% target by 10.5 pp) and 4-in-1 at age 5 was 81.4% (below the 95.0% target by 13.6 pp). For MMR at age 5, first-dose coverage was 95.5%, while second-dose coverage was 86.2% (below the 95.0% target by 8.8 pp), representing a 9.3 pp dose difference.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB, 52.4% of staged cancers were diagnosed at stage 1 or 2 in 2022 (4,642 of 8,863 known-stage cases), 22.6 pp below the 75.0% national ambition (England 55.3%). Known-stage share was 74.6% (8,863 of 11,883 cases). Early-stage share fell 1.2 pp from 2013 to 2022, requiring 2,005.2 extra early-stage diagnoses yearly to reach the ambition. Stage data was not captured at PCN level. Cervical screening coverage in women aged 25-49 is 62.5% (England 66.8%), falling 2.7% over 2023 to 2025 (England -1.0%), with 45.9% at Park View Surgery, 54.2% at Gutteridge Medical Centre, and 54.9% at The New Hall Lane Practice.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Lancashire Teaching Hospitals NHS Foundation Trust, 75.0415% of patients met the 62-day referral to treatment standard (10.0 pp below the 85.0% target), while the ICB achieved 73.619% (11.4 pp below target). For the 28-day faster diagnosis standard, the trust achieved 82.8957% (7.9 pp above the 75.0% standard) and the ICB reached 78.3901% (3.4 pp above standard). On the 31-day combined treatment standard, the trust attained 89.4327% (6.6 pp below the 96.0% standard), compared to 93.6241% across the ICB (2.4 pp below standard). These provider metrics describe acute system performance rather than PCN delivery.
| Pathways within standard (%) | Lancashire | East Lancashire | Blackpool | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.90 | 81.50 | 71.38 | 78.39 | 79.32 |
| 31-day treatment (96%) | 89.43 | 98.11 | 97.96 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 75.04 | 73.16 | 67.48 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Lancashire | East Lancashire | Blackpool | England |
|---|---|---|---|---|
| MRI | 2.41 | 0.43 | 21.80 | 21.40 |
| CT | 14.97 | 0.15 | 16.49 | 9.92 |
| Echocardiography | 13.85 | 0.00 | 7.57 | 28.48 |
| Colonoscopy | 0.00 | 0.95 | 13.08 | 30.83 |
| Gastroscopy | 0.00 | 1.16 | 12.47 | 29.02 |
| All 15 DM01 tests | 26.65 | 3.25 | 26.54 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In the provisional June 2026 Community Services Dataset, adults aged 65 and over accounted for 56.9% of community contacts among Preston borough residents (72,000 of 126,445 contacts). These borough-level resident figures describe wider community activity rather than PCN-specific service delivery.
Practice variation and patient experience
Phone access spans 61.1 pp across practices, alongside wide variation in clinical achievement
In 2025/26, QOF overall achievement ranged from 85.3% at Dr Ali Guttridge Medical Centre to 99.1% at Kingsfold Medical Centre. Vaccination and immunisation domain achievement spanned 76.7 pp, from 15.6% at Park View Surgery to 92.3% at Kingsfold Medical Centre. High overall points awards may conceal marked inter-practice differences in frontline preventive delivery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Kingsfold | 93 | 16.0 | 87.0% | 80.3% | 97.4% |
| New Hall Lane | 84 | 89.7 | 84.1% | 79.7% | 86.6% |
| Lane Ends Surgery | 106 | 43.0 | 56.3% | 74.9% | 81.5% |
| St. Mary's | 107 | 36.6 | 80.8% | 77.9% | 79.6% |
| Gutteridge | 90 | 96.1 | 78.0% | 78.3% | 77.8% |
| Briarwood | 91 | 27.5 | 65.8% | 83.6% | 76.3% |
| Park View Surgery | 99 | 82.0 | 71.3% | 73.4% | 74.5% |
| Dr Ali Guttridge | 102 | 95.9 | 63.8% | 71.0% | 73.4% |
| Park Medical | 112 | 55.0 | 62.7% | 71.7% | 72.7% |
| North Preston | 117 | 28.5 | 25.9% | 76.9% | 70.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
14 of 25 measures trail England on three-year change, led by asthma reviews
Fourteen of 25 compared measures trail England over three years. The widest relative shortfall is in annual asthma reviews, which fell 6.1% over 2023 to 2025 while England rose +4.4% (a lag of 10.58 points), leaving current coverage at 63.1% (England 65.7%). Learning disability register growth (+1.3%) also lagged England (+5.4%). Conversely, heart failure reviews improved +15.3% over three years (England +8.7%) to 81.0%, severe mental illness BMI recording rose +10.2 pp (England +5.1 pp), and under-80 blood pressure control grew +8.6% (England +3.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Learning disability register
COPD reviews
Diabetes statin (no CVD)
QRISK statin treatment
Heart failure reviews
BP control, under 80
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Preston | Asset | PCN | Preston |
|---|---|---|---|---|---|
| Care homes (catchment) | 44 (1,427 beds) | n/a | Schools (catchment) | 123 | n/a |
| Children's centres | 7 | 8 | Places of worship | 97 | 95 |
| Libraries | 5 | 5 | Primary schools (LA maintained) | 38 | 36 |
| Primary academies | 13 | 15 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Preschool MMR second-dose recall
At age 5 (cohort 247), MMR coverage drops 9.3 pp from 95.5% (dose 1) to 86.2% (dose 2, 8.8 pp below the 95.0% target), reaching 21.4 pp at Dr Ali Guttridge Medical Centre. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Standardised annual asthma review recall
Asthma reviews fell 6.1% over 2023 to 2025 (England +4.4%) to 63.1% (Preston 66.8%, England 65.7%), leaving an unadjusted scale gap of 2,052 patients across the 5,566 register. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register validation
Learning disability prevalence is 0.6% (565 patients; Preston 0.7%, England 0.6%), growing +1.3% over 2023 to 2025 (England +5.4%), with a benchmark gap range of -2 to +130 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Age-stratified case-finding review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Core20 healthcare outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Phone access and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Preschool MMR second-dose recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Standardised annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
